Publicacións en colaboración con investigadores/as de University of Amsterdam (15)

2023

  1. Antithrombotic Strategy in Secondary Prevention for High-Risk Patients with Previous Acute Coronary Syndrome: Overlap between the PEGASUS Eligibility and the COMPASS Eligibility in a Large Multicenter Registry

    American Journal of Cardiovascular Drugs, Vol. 23, Núm. 1, pp. 77-87

  2. Optimal medical therapy improves outcomes in patients with diabetes mellitus and acute myocardial infarction

    Diabetes Research and Clinical Practice, Vol. 203

2022

  1. Safety and efficacy of different P2Y12 inhibitors in patients with acute coronary syndromes stratified by the PRAISE risk score: a multicentre study

    European heart journal. Quality of care & clinical outcomes, Vol. 8, Núm. 8, pp. 881-891

2021

  1. Evaluation of optimal medical therapy in acute myocardial infarction patients with prior stroke

    Therapeutic Advances in Chronic Disease, Vol. 12

  2. Machine learning-based prediction of adverse events following an acute coronary syndrome (PRAISE): a modelling study of pooled datasets

    The Lancet, Vol. 397, Núm. 10270, pp. 199-207

  3. Ticagrelor or Clopidogrel After an Acute Coronary Syndrome in the Elderly: A Propensity Score Matching Analysis from 16,653 Patients Treated with PCI Included in Two Large Multinational Registries

    Cardiovascular Drugs and Therapy, Vol. 35, Núm. 6, pp. 1171-1182

2020

  1. Average daily ischemic versus bleeding risk in patients with ACS undergoing PCI: Insights from the BleeMACS and RENAMI registries

    American Heart Journal, Vol. 220, pp. 108-115

  2. Efficacy and Safety of Clopidogrel, Prasugrel and Ticagrelor in ACS Patients Treated with PCI: A Propensity Score Analysis of the RENAMI and BleeMACS Registries

    American Journal of Cardiovascular Drugs, Vol. 20, Núm. 3, pp. 259-269

  3. Impact of renin-angiotensin system blockade on the prognosis of acute coronary syndrome based on left ventricular ejection fraction

    Revista espanola de cardiologia (English ed.), Vol. 73, Núm. 2, pp. 114-122

  4. Incidence, predictors and prognostic impact of intracranial bleeding within the first year after an acute coronary syndrome in patients treated with percutaneous coronary intervention

    European Heart Journal: Acute Cardiovascular Care, Vol. 9, Núm. 7, pp. 764-770

  5. P2Y12 inhibitors in acute coronary syndrome patients with renal dysfunction: an analysis from the RENAMI and BleeMACS projects

    European heart journal. Cardiovascular pharmacotherapy, Vol. 6, Núm. 1, pp. 31-42

  6. The impact of optimal medical therapy on patients with recurrent acute myocardial infarction: Subanalysis from the BleeMACS study

    International Journal of Cardiology, Vol. 318, pp. 1-6

2018

  1. Development and external validation of a post-discharge bleeding risk score in patients with acute coronary syndrome: The BleeMACS score

    International Journal of Cardiology, Vol. 254, pp. 10-15

  2. Prediction of Post-Discharge Bleeding in Elderly Patients with Acute Coronary Syndromes: Insights from the BleeMACS Registry

    Thrombosis and Haemostasis, Vol. 118, Núm. 5, pp. 929-938

2016

  1. Safety and effectiveness of the new P2Y12r inhibitor agents vs clopidogrel in ACS patients according to the geographic area: East Asia vs Europe

    International Journal of Cardiology, Vol. 220, pp. 488-495